{
    "root": "c313e69a-3fa0-4667-b934-ffd359d09a07",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Divalproex sodium"
    },
    "value": "20250326",
    "ingredients": [
        {
            "name": "DIVALPROEX SODIUM",
            "code": "644VL95AO6"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "HYPROMELLOSE 2208 (100 MPA.S)",
            "code": "B1QE5P712K"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "POLYDEXTROSE",
            "code": "VH2XOU12IE"
        }
    ],
    "indications": "divalproex sodium extended-release tablets indicated : acute treatment manic mixed episodes associated bipolar disorder , without psychotic features ( 1.1 ) monotherapy adjunctive therapy complex partial seizures simple complex absence seizures ; adjunctive therapy patients multiple seizure types include absence seizures ( 1.2 ) prophylaxis migraine headaches ( 1.3 )",
    "contraindications": "divalproex sodium extended-release tablets extended-release product intended once-a-day oral . divalproex sodium extended-release tablets swallowed whole crushed chewed .",
    "warningsAndPrecautions": "divalproex sodium extended-release tablets usp , 250 mg white white , oval shaped film-coated tablets , imprinted “ 49 ” one side edible blue ink plain side . bottles 100 ndc 16714-484-01 bottles 500 ndc 16714-484-02 divalproex sodium extended-release tablets usp , 500 mg grey colored , oval shaped film-coated tablets , imprinted “ 50 ” one side edible blue ink plain side . bottles 100 ndc 16714-485-01 bottles 500 ndc 16714-485-02 recommended storage : store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . protect light .",
    "adverseReactions": "divalproex sodium extended-release tablets administered patients hepatic disease significant hepatic dysfunction [ ( 5.1 ) ] . divalproex sodium extended-release tablets contraindicated patients known mitochondrial disorders caused mutations mitochondrial dna polymerase γ ( polg ; e.g . , alpers-huttenlocher syndrome ) children two years age suspected polg-related disorder [ ( 5.1 ) ] . divalproex sodium extended-release tablets contraindicated patients known hypersensitivity [ ( 5.12 ) ] . divalproex sodium extended-release tablets contraindicated patients known urea cycle disorders [ ( 5.6 ) ] . prophylaxis migraine headaches : divalproex sodium extended-release tablets contraindicated women pregnant women childbearing potential using effective contraception [ ( 5.2 , 5.3 , 5.4 ) ( 8.1 ) ] .",
    "indications_original": "Divalproex sodium extended-release tablets are indicated for: Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features (1.1) Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures (1.2) Prophylaxis of migraine headaches (1.3)",
    "contraindications_original": "Divalproex sodium extended-release tablets are an extended-release product intended for once-a-day oral administration. Divalproex sodium extended-release tablets should be swallowed whole and should not be crushed or chewed.",
    "warningsAndPrecautions_original": "Divalproex Sodium Extended-Release \n                      Tablets USP, 250 mg  are white to off white, oval shaped film-coated tablets, imprinted with “I 49” on one side with edible blue ink and plain on other side.\n                              Bottles of 100                           NDC 16714-484-01          Bottles of 500                           NDC 16714-484-02          \n                     Divalproex Sodium Extended-Release \n                      Tablets USP, 500 mg  are grey colored, oval shaped film-coated tablets, imprinted with “I 50” on one side with edible blue ink and plain on other side. \n                              Bottles of 100                           NDC 16714-485-01         Bottles of 500                           NDC 16714-485-02         Recommended Storage: Store at  20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.",
    "adverseReactions_original": "Divalproex sodium extended-release tablets should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)]. \n                     Divalproex sodium extended-release tablets are  contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)]. \n                     Divalproex sodium extended-release tablets are contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.12)].\n                     Divalproex sodium extended-release tablets are contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6)].\n                     For use in prophylaxis of migraine headaches: Divalproex sodium extended-release tablets are contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (5.2, 5.3, 5.4)\n                         and \n                        \n                           Use in Specific Populations (8.1)\n                        \n                        ]."
}